odanacatib Articles

Thought leader views on new osteoporosis and osteopenia treatments

5 April 2013

ASBMR 2012: Anabolics and post-marketing studies

25 October 2012

New data on Amgen's Prolia and Merck & Co's odanacatib presented at ASBMR meeting

15 October 2012

Merck & Co closes odanacatib trial early on good results in osteoporosis

13 July 2012

Merck & Co highlights pipeline progress; plans eight US filings in 2012-

11 November 2011

Showing 1-5 of 5 articles

Go to beginningPrevious
  • 1
NextGo to end